RGC Reference HKU3/CRF/11R please insert ref. above

# The Research Grants Council of Hong Kong Collaborative Research Fund Group Research Projects Completion Report

(for completed projects only)

# **Part A:** The Project and Investigator(s)

## 1. Project Title

#### Liver Transplantation Research Centre: A Multidisciplinary Study for Liver Graft Injury

2. Investigator(s) and Academic Department/Units Involved (please highlight approved changes in the composition of the project team and quote the date when RGC granted approval of such changes)

|                 |                     |                               | Average number of     |
|-----------------|---------------------|-------------------------------|-----------------------|
|                 |                     |                               | hours per week        |
|                 |                     |                               | spent on this project |
|                 |                     |                               | in the current        |
| Research Team   | Name/Post           | Unit/Department/Institution   | reporting period      |
| Project         | Chung-Mau LO        | Department of Surgery         | 4                     |
| Coordinator     | Chair Professor     | The University of Hong Kong   |                       |
| Co-Principal    | Kwan MAN            | Department of Surgery         | 8                     |
| investigator(s) | Professor           | HKU                           |                       |
|                 |                     |                               |                       |
|                 | Xin-Yuan GUAN       | Department of Clinical        | 5                     |
|                 | Professor           | Oncology, HKU                 |                       |
|                 | Aimin XII           | Department of Medicine        | 3                     |
|                 | Professor           | HKU                           | 5                     |
|                 |                     |                               |                       |
|                 | Qi-Zhou LIAN        | Department of Ophthalmology   | 4                     |
|                 | Assistant Professor | HKU                           |                       |
|                 |                     |                               |                       |
|                 | Nathalie WONG       | Department of Anatomical and  |                       |
|                 | Professor           | Cellular Pathology, CUHK      | 2                     |
|                 |                     | Demonstration of Madiation of |                       |
|                 | Jun YU<br>Drofossor | Therement of Medicine &       | C                     |
|                 | Protessor           | Inerapeutics, CUHK            | 0                     |
|                 |                     |                               |                       |

# **<u>CRF 8G</u>** (Revised Sep 15) **3. Project Duration**

|   | Original     | Revised      | Date of RGC Approval |
|---|--------------|--------------|----------------------|
| Project Start Date                              | June 1, 2012 |              | ( 1110) 00 410100)   |
| Project Completion Date                         | May 31, 2015 | Nov 30, 2015 | April 20, 2016       |
| Duration (in month)                             | 36 months    | 42 months    |                      |
| Deadline for Submission<br>of Completion Report |              | Nov 30, 2016 |                      |

# CRF 8G(Revised Sep 15)Part B:The Final Report

# 5. **Project Objectives**

#### 5.1 Objectives as per original application

- 1. To explore the biological implications of acute phase inflammatory response on the liver microenvironment and tumor behavior by investigating the circulating immue-cells in a series of in vivo and in vitro functional studies together with prospective clinical investigations.
- 2. To study the impact of acute phase liver graft injury on the induction of late phase chemoresistance after liver transplantation. Elucidation of cross-talks among inflammatory networking, endoplasmic reticulum stress and drug resistance will be carried out in a series of animal experiments and findings on mechanistic actions will be validated in clinical studies.
- 3. To characterize the cellular signaling pathways involved in fatty liver graft injury with liver regeneration impairment, nonalcoholic steatohepatitis (NASH) development and late phase liver fibrosis in various animal models and clinical series.
- 4. To define circulating markers including microRNA signatures associated with acute phase inflammatory injury and prediction of tumor recurrence and metastasis after liver transplantation.
- 5. To investigate the potentials of stem cell (hiPSCs-MSCs) therapies both for tissue repair during liver regeneration and for anti-inflammation together with anti-tumor recurrence as a novel pro-drug vehicle (MSCs-GPx3) to attenuate acute phase liver graft injury and prevent late phase tumor recurrence.
- 5.2 Revised objectives

Date of approval from the RGC: March 2012

Reasons for the change: Since more than 50% of the proposed budget has been cut, we have to remove the original objective 2 from the proposal. There will be numbers of animal models and in vitro functional experiments involved in the study of acute phase liver graft injury inducing late phase chemoresistance after liver transplantation. It will be difficult to achieve this objective using current budget. We would like to seek other funding source to conduct this part of the study.

**Current Objectives:** 

- 1. To explore the biological implications of acute phase inflammatory response on the liver microenvironment and tumor behavior by investigating the circulating immue-cells in a series of in vivo and in vitro functional studies together with prospective clinical investigations.
- 2. To characterize the cellular signaling pathways involved in fatty liver graft injury with liver regeneration impairment, nonalcoholic steatohepatitis (NASH) development and late phase liver fibrosis in various animal models and clinical series.
- 3. To define circulating markers including microRNA signatures associated with acute phase inflammatory injury and prediction of tumor recurrence and metastasis after liver transplantation.
- 4. To investigate the potentials of stem cell (hiPSCs-MSCs) therapies both for tissue repair during liver regeneration and for anti-inflammation together with anti-tumor recurrence as a novel pro-drug vehicle (MSCs-GPx3) to attenuate acute phase liver graft injury and prevent late phase tumor recurrence.

## CRF 8G (Revised Sep 15)

# 6. Research Outcome

6.1 Major findings and research outcome

(maximum 1 page; please make reference to Part C where necessary)

# 1. The molecular signatures linked graft injury to tumor recurrence, induction of chemoresistance and NASH development

The molecular mechanisms of marginal liver graft regulating tumor recurrence, promoting chemoresistance and NASH development have been elucidated by a series of in vivo animal experiments and in vitro functional studies. Their clinical relevance has been also well validated in our clinical cohorts. We first reported that CXCL10/CXCR3 signaling mobilized circulating Tregs at early phase during liver graft injury promoted late phase tumor recurrence after transplantation (Li CX, et al, J Hepatology 2016; Rising Star Award in ILTS2016). We also demonstrated that M1 macrophages and Bregs play important roles for tumor growth and invasion (Shao et al., Cancer Letter 2015; Yeung et al., J Hepatology 2015). The up-regulation of CXCL10 in early-phase of liver transplantation can promote chemoresistance of HCC (Geng et al., Oncotarget 2016). We have also identified important mechanisms of carcinogenesis, metastasis and chemoresistance in liver cancer that will be valuable for development of effective therapeutic strategies to combat HCC recurrence (Chen et al., Nature Medicine 2013; Liu et al., Hepatology, 2013; Liu et al., Gastroenterology, 2014; Ng et al., Mol Cancer Therapeutics 2014; Qi et al., Oncotarget 2014). We have characterized the pathological mechanism and therapeutic potential of macrophages in NASH (Wu et al., Expert Opin Ther Targets 2016), the mechanism of CXCL10/CXCR3-mediated NASD development (Zhang et al., J Hepatology 2014; Zhang et al., J Hepatology 2016), and the mechanism of obesity-associated hepatocarcinogenesis (Shen et al., Oncogene 2016).

# 2. Distinct mechanisms regulating acute phase fatty liver graft injury, regeneration impairment and development of graft fibrosis

The acute phase inflammatory signaling plays critical roles on marginal liver graft injury. We have identified several important molecular targets leading to acute phase fatty liver graft injury including Lcn2, AR and RAP1 (Cheng et al., Ann Surg 2014; Li et al., Ann Surg 2014; Li et al., J Hepatology 2016). Targeted inhibition of these targets could reduce the acute phase hepatic injury via suppression of immune response. We also demonstrated that microRNA-29b could prevent liver fibrosis through attenuating stellate cell activation (Wang et al., Oncotarget 2014). The role of oval cells in contributing to fibrogenesis of marginal liver grafts under dynamic regulation of aldose reductase and notch signaling was also explored (Liu et al., J Hepatology, under review).

#### 3. Circulating biomarkers bridging inflammatory responses and tumor invasiveness

The potential circulating markers including microRNA profiling and protein marker associated with acute phase inflammatory injury and prediction of tumor recurrence and metastasis after liver transplantation have been identified. We identified post-liver transplantation early-phase circulating miR-1246 which is a novel indicator of early-phase hepatic injury and a significant predictor for late-phase HCC recurrence after liver transplantation (Ng et al., Oncotarget 2016). We also determined that plasma level of GPX3 can serve as a circulating biomarker for both small-for-size liver graft injury and HCC recurrence as well as survival of HCC recipients after liver transplantation (Qi et al., Theranostics 2016). We demonstrated that down-regulation of GPX3 after liver transplantation could be an important mechanism contributing to HCC invasiveness (Qi et al., Theranostics 2016). In addition, we identified that circulating fibroblast growth factor 21 is a sensitive biomarker for severe ischemia/reperfusion injury after liver transplantation (Ye et al., Sci Report 2016).

#### 4. hiPSC-MSCs therapies for tissue repair during regeneration

We demonstrated the repair potential of hiPSC-MSCs in different cell types such as airway epithelial cells and myocardial cells (Li et al., Am J Respir Cell Mol Biol. 2014; Liang et al., Cell Death Dis. 2015; Zhang et al., Stem Cell Reports. 2016; Li et al., J Cell Mol Med. 2016). Importantly, we applied hiPSC-MSCs to deliver GPX3 protein in HCC cells that could specially overexpress GPX3 protein in HCC cells and significantly suppress HCC growth in *in vivo* animal model (Qi et al., Oncotarget 2014). We also demonstrated that hiPSC-MSCs can promote liver regeneration and repair through mediating cell proliferation and macrophage polarization (Ma et al., manuscript in preparation).

# CRF 8G (Revised Sep 15)

6.2 Potential for further development of the research and the proposed course of action *(maximum half a page)* 

We would like to further develop the following research areas for liver transplantation:

- 1. To understand the role of regional specialization of immune system in tumor recurrence after liver transplantation by the approach of systems biology integrated with a series of clinical, basic and translational studies. The new concept of immunotherapies will be developed by educating the intragraft immune micro-environment to prevent tumor recurrence after liver transplantation.
- 2. To establish the novel therapeutics to overcome graft injury by using engineered cell therapy targeting for regional tissue repair and promoting functional liver regeneration.
- 3. To build a risk model for predicting patient outcomes after liver transplantation (graft injury, disease recurrence and patient survival) based on the molecular, immunological and biological features of the liver donors and recipients
  - Proposed course of action: To apply for TBRS grant for the further developments.
- 6.3 Research collaboration achieved (please give details on the achievement and its relevant impact)

## The synergism and collaborations among the PC/Co-PIs



# **National Collaborations:**

<u>Research area: Artificial Organ Support</u> State Key Laboratory for Infection Diseases Zhejiang University (ZJU) China

- MOU signed between State Key Laboratory for Infection Diseases and Laboratory for Organ Transplantation and Regeneration
- Exchange students/fellows trained in HKU
- Scientific Symposiums/Congresses jointly organized by ZJU

# **Regional Collaboration:**

<u>Research area: Application of lipic metabolomic analysis in graft injury and cancer</u> State Key Laboratory of Quality Research in Chinese Medicine Macau University of Science and Technology (MUST) Macau, China

• Scientific Symposiums jointly organized by MUST and HKU

# **International Collaborations:**

Established: International Liver Transplantation consortium

Research area: Transplantation and Cancer Immunology

Established: Collaborations with: INSERM UMR 1064-Center for Research in Transplantation and Immunology

• We have jointly held the International Symposium of Transplantation & Cancer Immunology (ISTC) in Hong Kong, 18-20 May, 2015.

Taken together, the established collaborations among local investigators and national, regional as well as international scholars will enable us to further develop the advance research in the field of organ transplantation.

# 7. The Layman's Summary

(describe <u>in layman's language</u> the nature, significance and value of the research project, in no more than 200 words)

Liver transplantation is a life-saving treatment for patients with end stage liver diseases including liver cancer. However, graft injury is the key issue, which may cause graft dysfunction and fibrosis and promote cancer recurrence. In current study, we have explored the cellular and molecular mechanisms of liver graft injury after transplantation. We have successfully identified the novel circulating biomarkers indicating acute phase graft injury and predicting late phase tumor recurrence and metastasis after transplantation. The potentials of stem cell therapy for graft regeneration have been also explored. The findings from this project will perfect the outcome of *liver transplantation* by addressing the issue of *graft injury* through integrated *clinical, basic* and *translational* research. It will be important to develop novel therapeutic strategies for clinical liver transplantation in near future.

# <u>CRF 8G</u> (Revised Sep 15) Part C: Research Output

# 8. Peer-reviewed journal publication(s) arising <u>directly</u> from this research project

(Please attach a copy of the publication and/or the letter of acceptance if not yet submitted in the previous progress report(s). All listed publications must acknowledge RGC's funding support by quoting the specific grant reference.)

## Summary of Output:

<u>Publication</u> 30 peer-reviewed international articles, total impact factor =241.347

Abstracts for international conferences

58 abstracts

<u>Students</u> 22 postgraduate student trained (20 PhD and 2 MPhil)

Awards (Total 44 Awards)

- 1. Awards of international conferences (Mentor-Mentee Awards, Rising Star Award, Young Investigator Awards, Best presentation Awards): 26
- Achievement Awards for PIs (The Natural Science Awards (First Class), The Chinese Medical Technology Award (First Class), State Scientific and Technological Progress Award (Second Class)): 9
- 3. Achievement Awards for students (University Scholarships and Best Research Output Awards):9

| The L       | atest Status o | f Publica | tions       | Author(s)      | Title and          | Submitted | Attached | Acknowle   | Accessible    |
|-------------|----------------|-----------|-------------|----------------|--------------------|-----------|----------|------------|---------------|
| Year of     | Year of        | Under     | Under       | (denote the    | Journal/Book       | to RGC    | to this  | dged the   | from the      |
| publication | Acceptance     | Review    | Preparation | corresponding  | (with the volume,  | (indicate | report   | support of | institutional |
| -           | (For paper     |           | (optional)  | author with an | pages and other    | the year  | (Yes or  | RGC (Yes   | repository    |
|             | accepted but   |           |             | asterisk*)     | necessary          | ending of | No)      | or No)     | (Yes or No)   |
|             | not yet        |           |             |                | publishing details | the       |          |            |               |
|             | published)     |           |             |                | specified)         | relevant  |          |            |               |
|             |                |           |             |                |                    | progress  |          |            |               |
|             |                |           |             |                |                    | report)   |          |            |               |
|             |                |           |             |                |                    |           |          |            |               |
| 2016        |                |           |             | Oi X, Ng KT,   | The Clinical       | No        | ves      | ves        | ves           |
|             |                |           |             | Shao Y, Li     | Significance and   |           | 2        | 5          | 5             |
|             |                |           |             | CX, Geng W,    | Potential          |           |          |            |               |
|             |                |           |             | Ling CC, Ma    | Therapeutic        |           |          |            |               |
|             |                |           |             | YY. Liu XB.    | Role of GPx3 in    |           |          |            |               |
|             |                |           |             | Liu H, Liu J,  | Tumor              |           |          |            |               |
|             |                |           |             | Yeung WH,      | Recurrence after   |           |          |            |               |
|             |                |           |             | Lo CM,         | Liver              |           |          |            |               |
|             |                |           |             | Man K*.        | Transplantation.   |           |          |            |               |
|             |                |           |             |                | Theranostics       |           |          |            |               |
|             |                |           |             |                | 2016,              |           |          |            |               |
|             |                |           |             |                | 6(11):1934-46.     |           |          |            |               |
| 2016        |                |           |             | Li CX, Ling    | CXCL10/CXCR        | No        | yes      | yes        | yes           |
|             |                |           |             | CC, Shao Y,    | 3 signaling        |           | -        | -          | -             |
|             |                |           |             | Xu A, Li XC,   | mobilized-regula   |           |          |            |               |
|             |                |           |             | Ng KT, Liu     | tory T cells       |           |          |            |               |
|             |                |           |             | XB, Ma YY,     | promote liver      |           |          |            |               |

|      | I / |  |                         |     |     |     |     |
|------|-----|--|-------------------------|-----|-----|-----|-----|
|      |     | Qi X, Liu H,                                       | tumor                   |     |     |     |     |
|      |     | Liu J, Yeung                                       | recurrence after        |     |     |     |     |
|      |     | OW, Zhai Y,  | transplantation.        |     |     |     |     |
|      |     | <u>Lo CM</u> ,<br>M K*                             | Journal of              |     |     |     |     |
|      |     | <u>Man K</u> *.                                    | Hepatology              |     |     |     |     |
|      |     |  | 2016, May 28.           |     |     |     |     |
|      |     |  | pii:<br>S0169 9279(16)  |     |     |     |     |
|      |     |  | 30244 6                 |     |     |     |     |
| 2016 |     | Ng KT I o  | 50244-0.<br>Farly phase | No  | VAC | VAC | VAS |
| 2010 |     | $\frac{\log 11}{CM}$                               | circulating             | INU | yes | yes | yes |
|      |     | $\underline{\text{CMI}}, \underline{\text{Wollg}}$ | miRNAs predict          |     |     |     |     |
|      |     | $\underline{X}$ , Liu XB.                          | tumor                   |     |     |     |     |
|      |     | Geng W.  | recurrence and          |     |     |     |     |
|      |     | Yeung OW,  | survival of             |     |     |     |     |
|      |     | Chan SC,   | hepatocellular          |     |     |     |     |
|      |     | <u>Man K</u> *.                                    | carcinoma               |     |     |     |     |
|      |     |  | patients after          |     |     |     |     |
|      |     |  | liver                   |     |     |     |     |
|      |     |  | transplantation.        |     |     |     |     |
|      |     |  | Oncotarget              |     |     |     |     |
|      |     |  | 2016,                   |     |     |     |     |
|      |     |  | 7(15):19824-39.         |     |     |     |     |
| 2016 |     | Li CX, <u>Lo</u>                                   | Repressor and           | No  | yes | yes | yes |
|      |     | <u>CM</u> , <u>Lian</u>                            | activator protein       |     |     |     |     |
|      |     | $\underline{\mathbf{QZ}}$ , Ng K1,                 | accelerates             |     |     |     |     |
|      |     | Liu XB,<br>Cong W. Mo                              | nepatic ischemia        |     |     |     |     |
|      |     | VV O; V  | injury by               |     |     |     |     |
|      |     | II, QIA,<br>Ling CC                                | nijuly by               |     |     |     |     |
|      |     | Yeung OW   | neutrophil              |     |     |     |     |
|      |     | Shao Y   | inflammatory            |     |     |     |     |
|      |     | Cheng O.   | response.               |     |     |     |     |
|      |     | Man K <sup>*</sup> .                               | Oncotarget              |     |     |     |     |
|      |     |  | 2016                    |     |     |     |     |
|      |     |  | 7(19):27711-23          |     |     |     |     |
| 2016 |     | Ye D, Li H,  | Circulating             | No  | yes | yes | yes |
|      |     | Wang Y, Jia  | Fibroblast              |     |     |     |     |
|      |     | W, Zhou J,   | Growth Factor           |     |     |     |     |
|      |     | Fan J, <u>Man</u>                                  | 21 Is A                 |     |     |     |     |
|      |     | <u><b>K</b></u> , Lo C,                            | Sensitive               |     |     |     |     |
|      |     | Wong C,  | Biomarker for           |     |     |     |     |
|      |     | I am KS <b>Xu</b>                                  | Jechemia/reperfu        |     |     |     |     |
|      |     | <b>L</b> ain KS, <u>Au</u><br><b>A</b> *           | sion Injury in          |     |     |     |     |
|      |     | <u>A</u>   | Patients with           |     |     |     |     |
|      |     |  | Liver                   |     |     |     |     |
|      |     |  | Transplantation.        |     |     |     |     |
|      |     |  | <i>Sci Rep</i> . 2016   |     |     |     |     |
|      |     |  | Jan 25;6:19776.         |     |     |     |     |
|      |     |  | doi:                    |     |     |     |     |
|      |     |  | 10.1038/srep197         |     |     |     |     |
|      |     | <br>   | 76.                     |     |     |     |     |
| 2016 |     | <br>Zhang X,                                       | CXC chemokine           | No  | yes | yes | yes |
|      |     | Han J, <u>Man</u>                                  | receptor 3              |     |     |     |     |
|      |     | <u><b>K</b></u> , Li X, Du                         | promotes                |     |     |     |     |
|      |     | J, Chu ES,   | steatohepatitis in      |     |     |     |     |

|      | <u> </u> |  |                          |     |     |     |     |
|------|----------|--|--------------------------|-----|-----|-----|-----|
|      |          | Go MY,   | mice through             |     |     |     |     |
|      |          | Sung JJ, <u>Yu</u>   | mediating                |     |     |     |     |
|      |          | <u>J</u> *   | inflammatory             |     |     |     |     |
|      |          |  | cytokines,               |     |     |     |     |
|      |          |  | macrophage and           |     |     |     |     |
|      |          |  | autophagy. J             |     |     |     |     |
|      |          |  | <i>Hepatol.</i> 2016     |     |     |     |     |
|      |          |  | Jan;64(1):160-7          |     |     |     |     |
|      |          |  | 0.                       |     |     |     |     |
| 2016 |          | Wu R,  | Pathophysiologi          | No  | yes | yes | yes |
|      |          | Nakatsu G,   | cal mechanisms           |     |     |     |     |
|      |          | Zhang X, <u>Yu</u>   | and therapeutic          |     |     |     |     |
|      |          | $\overline{\mathbf{J}}_{*}$                                      | potentials of            |     |     |     |     |
|      |          |  | macrophages in           |     |     |     |     |
|      |          |  | non-alcoholic            |     |     |     |     |
|      |          |  | steatohepatitis.         |     |     |     |     |
|      |          |  | Expert Opin              |     |     |     |     |
|      |          |  | Ther Targets.            |     |     |     |     |
|      |          |  | 2016 Jan                 |     |     |     |     |
|      |          | ~ -  | 22:1-12.                 |     |     |     |     |
| 2016 |          | Shen J, Tsoi   | Oncogenic                | No  | yes | yes | yes |
|      |          | H, Liang Q,  | mutations and            |     |     |     |     |
|      |          | Chu ES, Liu  | dysregulated             |     |     |     |     |
|      |          | D, Yu AC,  | pathways in              |     |     |     |     |
|      |          | Chan TF, Li  | obesity-associate        |     |     |     |     |
|      |          | X, Sung JJ,  | d hepatocellular         |     |     |     |     |
|      |          | Wong VW*,  | carcinoma.               |     |     |     |     |
|      |          | <u>Yu J</u> *  | Oncogene. 2016           |     |     |     |     |
|      |          |  | May 2. doi:              |     |     |     |     |
|      |          |  | 10.1038/onc.201          |     |     |     |     |
|      |          |  | 6.162. [Epub             |     |     |     |     |
|      |          |  | ahead of print]          |     |     |     |     |
| 2016 |          | Li X, Zhang  | iPSC-derived             | No  | yes | yes | yes |
|      |          | Y, Liang Y,  | mesenchymal              |     |     |     |     |
|      |          | Cui Y,   | stem cells exert         |     |     |     |     |
|      |          | Yeung SC, Ip   | SCF-dependent            |     |     |     |     |
|      |          | MS, I se HF,   | recovery of              |     |     |     |     |
|      |          | Lian Q, Mak  | cigarette                |     |     |     |     |
|      |          | JC   | smoke-induced            |     |     |     |     |
|      |          |  | apoptosis/prolife        |     |     |     |     |
|      |          |  | ration impalance         |     |     |     |     |
|      |          |  | in airway cells. J       |     |     |     |     |
|      |          |  | 2016 Sor 10              |     |     |     |     |
|      |          |  | 2010 Sep 19.             |     |     |     |     |
|      |          |  | 001:<br>10.1111/jamm 1   |     |     |     |     |
|      |          |  | 2062                     |     |     |     |     |
| 2015 |          | Geng W Lo  | 2702.<br>Interferon comm | No  | Vec | Voc | VOS |
| 2013 |          | $CM N_{\alpha} VT$   | a Inducible              | INU | yes | yes | yes |
|      |          | $\underline{CIVI}$ , $\underline{Vg} \mathbf{KI}$ ,<br>Ling CC O | Protein 10               |     |     |     |     |
|      |          | $X \downarrow C X$   | un-regulated by          |     |     |     |     |
|      |          | Zhai V Liu   | acute-phase              |     |     |     |     |
|      |          | XR Ma VV   | oraft injury             |     |     |     |     |
|      |          | Man K*   | induced                  |     |     |     |     |
|      |          | <u>171411 1X</u>   | late_nhace               |     |     |     |     |
|      |          |  | cienlatin                |     |     |     |     |
|      |          |  | resistance after         |     |     |     |     |
|      |          |  | LIGMMAILE AHEF           |     |     |     |     |

|      | ` |  |  |                   |     |             |                     | 1                   |
|------|---|--|--|-------------------|-----|-------------|---------------------|---------------------|
|      |   |  |  | liver             |     |             |                     |                     |
|      |   |  |  | transplantation.  |     |             |                     |                     |
|      |   |  |  | Oncotarget        |     |             |                     |                     |
|      |   |  |  | 2015,             |     |             |                     |                     |
|      |   |  |  | 6(29):28042-56.   |     |             |                     |                     |
| 2015 |   |  | Wang J. Liu                            | Overexpression    | No  | ves         | ves                 | ves                 |
| 2010 |   |  | M Chen L                               | of N-terminal     | 110 | <b>J</b> 08 | <i>J</i> <b>C</b> 5 | <i>j</i> <b>c</b> s |
|      |   |  | Chan TH                                | kinasa lika gana  |     |             |                     |                     |
|      |   |  | Liona I                                | magnetas          |     |             |                     |                     |
|      |   |  | Jiang L,                               | promotes          |     |             |                     |                     |
|      |   |  | Yuan YF,                               | tumorigenicity    |     |             |                     |                     |
|      |   |  | <u>Guan XY</u> *                       | of hepatocellular |     |             |                     |                     |
|      |   |  |  | carcinoma by      |     |             |                     |                     |
|      |   |  |  | regulating cell   |     |             |                     |                     |
|      |   |  |  | cycle             |     |             |                     |                     |
|      |   |  |  | progression and   |     |             |                     |                     |
|      |   |  |  | cell motility.    |     |             |                     |                     |
|      |   |  |  | Oncotarget        |     |             |                     |                     |
|      |   |  |  | 2015;6(3):1618-   |     |             |                     |                     |
|      |   |  |  | 30.               |     |             |                     |                     |
| 2015 |   |  | Jiang L.                               | HBP21. a          | No  | yes         | yes                 | yes                 |
|      |   |  | Kwong DL.                              | chaperone of      |     | -           | 2                   | 2                   |
|      |   |  | Li Y. Liu M                            | heat shock        |     |             |                     |                     |
|      |   |  | Yuan YF Li                             | protein 70        |     |             |                     |                     |
|      |   |  | Y Fu I                                 | functions as a    |     |             |                     |                     |
|      |   |  | Cuon XV*                               | tumor             |     |             |                     |                     |
|      |   |  | Guan AT                                | suppressor in     |     |             |                     |                     |
|      |   |  |  | hopotocollular    |     |             |                     |                     |
|      |   |  |  | nepatocentilar    |     |             |                     |                     |
|      |   |  |  | carcinoma.        |     |             |                     |                     |
|      |   |  |  | Carcinogenesis    |     |             |                     |                     |
|      |   |  |  | 2015;36(10):111   |     |             |                     |                     |
|      |   |  |  | 1-20.             |     |             |                     |                     |
| 2015 |   |  | Zhang Y, Yu                            | iPSC-MSCs         | No  | yes         | yes                 | yes                 |
|      |   |  | Z, Jiang D,                            | with High         |     |             |                     |                     |
|      |   |  | Liang X,                               | Intrinsic MIRO1   |     |             |                     |                     |
|      |   |  | Liao S,                                | and Sensitivity   |     |             |                     |                     |
|      |   |  | Zhang Z,                               | to TNF-α Yield    |     |             |                     |                     |
|      |   |  | Yue W, Li X,                           | Efficacious       |     |             |                     |                     |
|      |   |  | Chiu SM.                               | Mitochondrial     |     |             |                     |                     |
|      |   |  | Chai YH.                               | Transfer to       |     |             |                     |                     |
|      |   |  | Liang Y                                | Rescue            |     |             |                     |                     |
|      |   |  | Chow Y Han                             | Anthracycline-In  |     |             |                     |                     |
|      |   |  | S XII A TSP                            | duced             |     |             |                     |                     |
|      |   |  | HF Lian                                | Cardiomyonathy    |     |             |                     |                     |
|      |   |  | •••••••••••••••••••••••••••••••••••••• | Stom Coll         |     |             |                     |                     |
|      |   |  | <u>×</u> ·                             | Ranarta 2016      |     |             |                     |                     |
|      |   |  |  | Oct               |     |             |                     |                     |
|      |   |  |  | 11.7(4).740 762   |     |             |                     |                     |
| 2015 |   |  | T 1. 37                                | 11,7(4):749-763.  | ЪT  | _           | _                   |                     |
| 2015 |   |  | Liang $X$ ,                            | Activation of     | No  | yes         | yes                 | yes                 |
|      |   |  | Ding Y,                                | NKGI-ERBB4        |     |             |                     |                     |
|      |   |  | Zhang Y,                               | signaling         |     |             |                     |                     |
|      |   |  | Chai YH, He                            | potentiates       |     |             |                     |                     |
|      |   |  | J, Chiu SM,                            | mesenchymal       |     |             |                     |                     |
|      |   |  | Gao F, Tse                             | stem              |     |             |                     |                     |
|      |   |  | HF, <u>Lian Q</u> *                    | cell-mediated     |     |             |                     |                     |
|      |   |  |  | myocardial        |     |             |                     |                     |
|      |   |  |  | repairs           |     |             |                     |                     |
|      |   |  |  | following         |     |             |                     |                     |

|      | <b>`</b> | 1 / |     |   |                          |      |     |     |     |
|------|----------|-----|-----|---|--------------------------|------|-----|-----|-----|
|      |          |     |     |   | myocardial               |      |     |     |     |
|      |          |     |     |   | infarction. Cell         |      |     |     |     |
|      |          |     |     |   | Death Dis. 2015          |      |     |     |     |
|      |          |     |     |   | May 21;6:e1765.          |      |     |     |     |
|      |          |     |     |   | doi:                     |      |     |     |     |
|      |          |     |     |   | 10.1038/cddis.2          |      |     |     |     |
|      |          |     |     |   | 015.91.                  |      |     |     |     |
| 2014 |          |     |     | Tang CM,  | Management of            | No   | yes | yes | yes |
|      |          |     |     | Yau TO, <b>Yu</b>   | chronic hepatitis        |      | •   | •   | •   |
|      |          |     |     | J*  | B infection:             |      |     |     |     |
|      |          |     |     |   | Current                  |      |     |     |     |
|      |          |     |     |   | treatment                |      |     |     |     |
|      |          |     |     |   | guidelines.              |      |     |     |     |
|      |          |     |     |   | challenges, and          |      |     |     |     |
|      |          |     |     |   | new                      |      |     |     |     |
|      |          |     |     |   | developments             |      |     |     |     |
|      |          |     |     |   | World I                  |      |     |     |     |
|      |          |     |     |   | Gastroenterol            |      |     |     |     |
|      |          |     |     |   | 2014 May                 |      |     |     |     |
|      |          |     |     |   | 28.20(20).6262           |      |     |     |     |
|      |          |     |     |   | 78                       |      |     |     |     |
|      |          | Vec |     |   | Oval cells               | No   | Vec | Vec | Vec |
|      |          | 105 |     | CM  | contribute to            | 140  | yes | yes | yes |
|      |          |     |     | $\frac{\mathbf{C}\mathbf{W}\mathbf{I}}{\mathbf{C}\mathbf{H}\mathbf{E}\mathbf{N}\mathbf{G}}$   | fibrogenesis of          |      |     |     |     |
|      |          |     |     | Ng KT Shoo  | morginal liver           |      |     |     |     |
|      |          |     |     | $\mathbf{N}\mathbf{g}\mathbf{K}\mathbf{I}, \mathbf{S}\mathbf{I}\mathbf{a}0$   | marginal liver           |      |     |     |     |
|      |          |     |     | I, LICA,  | grans under              |      |     |     |     |
|      |          |     |     | Chung SK,   | dynamic<br>regulation of |      |     |     |     |
|      |          |     |     | $\operatorname{Ng} \operatorname{IO}, \underline{\mathbf{Y}} \underline{\mathbf{U}} \underline{\mathbf{J}},$ $\operatorname{Marr} \mathbf{W}^*$ | regulation of            |      |     |     |     |
|      |          |     |     | <u>Man K</u> *.   | aldose reductase         |      |     |     |     |
|      |          |     |     |   | and notch                |      |     |     |     |
|      |          |     |     |   | signaling.               |      |     |     |     |
|      |          |     |     |   | Journal of               |      |     |     |     |
|      |          |     |     |   | Hepatology               |      |     |     |     |
|      |          |     | Yes | Ma YY, Li   | Human induced            | No   | yes | yes | yes |
|      |          |     |     | CX, Geng W,   | pluripotent stem         |      |     |     |     |
|      |          |     |     | Q1 X, Ng KT,  | cells derived            |      |     |     |     |
|      |          |     |     | Yeung WH,   | mesenchymal              |      |     |     |     |
|      |          |     |     | <u>Lian QZ</u> , <u>Lo</u>  | stem cells               |      |     |     |     |
|      |          |     |     | <u>CM</u> , <u>Man</u>  | promote liver            |      |     |     |     |
|      |          |     |     | <u>K</u> *.   | regeneration and         |      |     |     |     |
|      |          |     |     |   | repair through           |      |     |     |     |
|      |          |     |     |   | mediating cell           |      |     |     |     |
|      |          |     |     |   | proliferation and        |      |     |     |     |
|      |          |     |     |   | macrophage               |      |     |     |     |
|      |          |     |     |   | polarization             |      |     |     |     |
| 2015 |          |     |     | Wang J, Chu   | microRNA-29b             | 2015 | No  | yes | yes |
|      |          |     |     | ES, Chen  | prevents liver           |      |     |     |     |
|      |          |     |     | HY, <u>Man K</u> ,  | fibrosis by              |      |     |     |     |
|      |          |     |     | Go MY,  | attenuating              |      |     |     |     |
|      |          |     |     | Huang XR,   | hepatic stellate         |      |     |     |     |
|      |          |     |     | Lan HY,   | cell activation          |      |     |     |     |
|      |          |     |     | Sung JJ, <u>Yu</u>  | and inducing             |      |     |     |     |
|      |          |     |     | <u>J</u> *  | apoptosis                |      |     |     |     |
|      |          |     |     |   | through                  |      |     |     |     |
|      |          |     |     |   | targeting                |      |     |     |     |
|      |          |     |     |   | PI3K/AKT                 |      |     |     |     |
|      |          |     |     |   | pathway.                 |      |     |     |     |

|      |  |  | Oncotarget.<br>2014 Oct 22. pii:<br>2621. [Epub<br>ahead of print]  |      |    |     |     |
|------|--|--|---|------|----|-----|-----|
| 2015 |  | Yeung OW,<br><u>Lo CM</u> , Ling<br>CC, Li CX,<br>Qi X, Ng KT,<br>Geng W,<br>Forbes S,<br><u>Guan XY</u> ,<br>Poon RT,<br>Fan ST, <u>Man</u><br><u>K</u> *.    | Alternatively<br>Activated (M2)<br>Macrophages<br>Promoted<br>Tumor Growth<br>and Invasiveness<br>in<br>Hepatocellular<br>Carcinoma.<br>Journal of<br>Hepatology<br>2015,<br>62:607-616.                    | 2015 | No | yes | yes |
| 2015 |  | Ng KT, Xu<br>A, Cheng Q,<br>Guo DY,<br>Lim ZX, Sun<br>CK, Fung<br>JH, Poon RT,<br>Fan ST, <u>Lo</u><br><u>CM, Man</u><br><u>K</u> *.                           | Clinical<br>relevance and<br>therapeutic<br>potential of<br>angiopoietin-like<br>protein 4 in<br>hepatocellular<br>carcinoma.<br><i>Molecular</i><br><i>Cancer</i> 2014,<br>13(1):196-213.                  | 2015 | No | yes | yes |
| 2015 |  | Ng KT, <u>Lo</u><br><u>CM</u> , Guo<br>DY, Qi X, Li<br>CX, Geng W,<br>Li XB, Ling<br>CC, Ma YY,<br>Yeung WH,<br>Shao Y, Poon<br>RT, Fan ST,<br><u>Man K</u> *. | Identification of<br>transmembrane<br>protein 98 as a<br>novel<br>chemoresistance<br>-conferring gene<br>in hepatocellular<br>carcinoma.<br>Molecular<br>Cancer<br>Therapeutics<br>2014,<br>13(5):1285-1297 | 2015 | No | yes | yes |
| 2014 |  | Qi X, Ng KT,<br>Lian QZ,<br>Liu XB, Li<br>CX, Geng W,<br>Ling CC, Ma<br>YY, Yeung<br>WH, Tu<br>WW, Fan<br>ST, <u>Lo CM</u> ,<br><u>Man K</u> *.                | Clinical<br>significance and<br>therapeutic<br>value of<br>Glutathione<br>peroxidase 3<br>(GPx3) in<br>hepatocellular<br>carcinoma.<br>Oncotarget<br>2014,<br>5(22):11103-111<br>20.                        | 2015 | No | yes | yes |

|      | Revised Se | p 13) |  |  |      |    |     |     |
|------|------------|-------|--|--|------|----|-----|-----|
| 2014 |            |       | Shao Y, <u>Lo</u><br><u>CM</u> , Ling<br>CC, Liu XB, | Regulatory B<br>cells accelerate<br>hepatocellular | 2015 | No | yes | yes |
|      |            |       | AC, Ma YY,<br>Li CX Fan                              | progression via<br>CD40/CD154                      |      |    |     |     |
|      |            |       | ST, <u>Man K</u> *.                                  | signaling  |      |    |     |     |
|      |            |       |  | pathway. Cancer<br>Letters 2014                    |      |    |     |     |
|      |            |       |  | 355(2):264-272.                                    |      |    |     |     |
| 2014 |            |       | Ye D, Wang   | Fibroblast   | 2015 | No | yes | yes |
|      |            |       | W, Man K,  | 21protects   |      |    |     |     |
|      |            |       | Lo CM,   | against  |      |    |     |     |
|      |            |       | Wang Y,  | acetaminophen-i                                    |      |    |     |     |
|      |            |       | Lani KS, <u>Au</u><br>A*                             | hepatotoxicity                                     |      |    |     |     |
|      |            |       | _  | by potentiating                                    |      |    |     |     |
|      |            |       |  | peroxisome   |      |    |     |     |
|      |            |       |  | ated receptor                                      |      |    |     |     |
|      |            |       |  | coactivator  |      |    |     |     |
|      |            |       |  | protein-1α-medi                                    |      |    |     |     |
|      |            |       |  | ated antioxidant                                   |      |    |     |     |
|      |            |       |  | Hepatology.  |      |    |     |     |
|      |            |       |  | 2014   |      |    |     |     |
|      |            |       |  | Sep;60(3):977-8                                    |      |    |     |     |
| 2014 |            |       | Liu M, Li Y,   | Allele-specific                                    | 2015 | No | yes | yes |
|      |            |       | Chen L,  | imbalance of                                       |      |    |     |     |
|      |            |       | Song Y. Fu   | stress-induced                                     |      |    |     |     |
|      |            |       | L, Zeng TT,  | growth inhibitor                                   |      |    |     |     |
|      |            |       | Dai YD, Zhu  | 1 associates with                                  |      |    |     |     |
|      |            |       | YH, LIY,<br>Chen J. Yuan                             | progression of<br>hepatocellular                   |      |    |     |     |
|      |            |       | YF, <u>Guan</u>                                      | carcinoma.   |      |    |     |     |
|      |            |       | <u>XY</u> *  | Gastroenterolog                                    |      |    |     |     |
|      |            |       |  | y<br>2014;146(4):108                               |      |    |     |     |
|      |            |       |  | 4-96.  |      |    |     |     |
| 2014 |            |       | Zhang X,<br>Shen L Man                               | CXCL10 plays a                                     | 2015 | No | Yes | Yes |
|      |            |       | <u>K</u> , Chu ES,                                   | inflammatory                                       |      |    |     |     |
|      |            |       | Yau TO,  | mediator and a                                     |      |    |     |     |
|      |            |       | Sung JC, Go<br>MY Deng I                             | non-invasive                                       |      |    |     |     |
|      |            |       | Lu L, Wong   | non-alcoholic                                      |      |    |     |     |
|      |            |       | VW, Sung JJ,   | steatohepatitis.                                   |      |    |     |     |
|      |            |       | Farrell G, <u>Yu</u><br><b>1</b> *                   | Journal of<br>Henetology                           |      |    |     |     |
|      |            |       | <u>J . '</u>   | 2014   |      |    |     |     |
|      |            |       |  | Dec;61(6):1365-                                    |      |    |     |     |
|      |            |       |  | 75.  |      |    |     |     |

CRF 8G (Revised Sep 15)

|      | $p_{1}$ |  |  |      |    |     |     |
|------|---------|--|--|------|----|-----|-----|
| 2014 |         | Li X, Zhang<br>Y, Yeung<br>SC, Liang Y,<br>Liang X,<br>Ding Y, Ip<br>MS, Tse HF,<br>Mak JC,<br><u>Lian Q*</u> .  | Mitochondrial<br>transfer of<br>induced<br>pluripotent stem<br>cell-derived<br>mesenchymal<br>stem cells to<br>airway epithelial<br>cells attenuates<br>cigarette<br>smoke-induced<br>damage. <i>Am J</i><br><i>Respir Cell Mol</i><br><i>Biol.</i> 2014<br>Sep;51(3):455-6<br>5 | 2015 | No | Yes | Yes |
| 2013 |         | Ling CC, Ng<br>KT, Shao Y,<br>Geng W,<br>Xiao JW, Lui<br>H, Li CX,<br>Liu XB, Ma<br>YY, Yeung<br>WH, Qi X,<br><u>Yu J, Wong</u><br><u>N</u> , Zhai Y,<br>Chan SC,<br>Poon RT,<br>Fan ST, <u>Lo</u><br><u>CM*, Man</u><br><u>K*</u> . | Post-transplant<br>Endothelial<br>Progenitor Cell<br>Mobilization via<br>CXCL10/CXCR<br>3 Signaling<br>Promotes Liver<br>Tumor Growth.<br><i>Journal of</i><br><i>Hepatology</i> .<br>doi:pii:<br>S0168-8278(13)<br>00612-0.10.1016<br>/j.jhep.2013.08.0<br>17                   | 2013 | No | Yes | yes |
| 2013 |         | Li CX, Ng<br>KT, Shao Y,<br>Liu XB, Ling<br>CC, Ma YY,<br>Geng W, Qi<br>X, Cheng Q,<br>Chung SK,<br><u>Lo CM</u> ,<br><u>Man K*</u> .  | The inhibition of<br>aldose reductase<br>attenuates<br>hepatic ischemia<br>reperfusion<br>injury through<br>reducing<br>inflammatory<br>response.<br><i>Annals of</i><br><i>Surgery</i> 2014,<br>260:317-328.  | 2013 | No | Yes | yes |
| 2013 |         | Cheng Q, Ng<br>KT, <b>Xu A</b> , Li<br>CX, Liu XB,<br>Guo DY,<br>Poon RT,<br>Fan ST, <u>Lo</u><br><u>CM</u> , <u>Man K</u> .   | The roles of<br>Lipocalin-2 in<br>small-for-size<br>fatty liver graft<br>injury.<br><i>Annals of</i><br><i>Surgery</i><br>2014, 260(6):<br>1062-1072.  | 2013 | No | Yes | yes |
| 2013 |         | Chen L, Li<br>Y, Lin CH,<br>Chan TH,<br>Chow RK,<br>Song Y, Liu  | Recoding RNA<br>editing of<br>AZIN1<br>predisposes to<br>hepatocellular  | 2013 | No | Yes | yes |

|      | <b>1</b> |                          |                             |      |    |     |     |
|------|----------|--------------------------|-----------------------------|------|----|-----|-----|
|      |          | M, Yuan YF,              | carcinoma.                  |      |    |     |     |
|      |          | Fu L. Kong               |                             |      |    |     |     |
|      |          | KL Oi L Li               | Nature                      |      |    |     |     |
|      |          | Y Zhang N                | Medicine 2013               |      |    |     |     |
|      |          | Tong AU                  | Eab: $10(2):200.1$          |      |    |     |     |
|      |          | Tolig AH,                | Fe0,19(2).209-1             |      |    |     |     |
|      |          | Kwong DL,                | 0.                          |      |    |     |     |
|      |          | <u>Man K</u> , <u>Lo</u> |                             |      |    |     |     |
|      |          | <u>CM</u> , Lok S,       |                             |      |    |     |     |
|      |          | Tenen DG,                |                             |      |    |     |     |
|      |          | Guan XY*.                |                             |      |    |     |     |
| 2013 |          | Liu L, Dai Y,            | Maelstrom                   | 2013 | No | Yes | ves |
|      |          | Chen I Zeng              | promotes                    |      |    |     | 5   |
|      |          | TLiY                     | henatocellular              |      |    |     |     |
|      |          | Chen I 7hu               | carcinoma                   |      |    |     |     |
|      |          |                          |                             |      |    |     |     |
|      |          | IH, LIJ, LI              | metastasis by               |      |    |     |     |
|      |          | Y, X1e D,                | inducing                    |      |    |     |     |
|      |          | Yuan YF,                 | epithelial-mesen            |      |    |     |     |
|      |          | <u>Guan XY*</u>          | chymal                      |      |    |     |     |
|      |          |                          | transition via              |      |    |     |     |
|      |          |                          | Akt/GSK-3 <sup>β</sup> /sna |      |    |     |     |
|      |          |                          | il signaling.               |      |    |     |     |
|      |          |                          | Henatology                  |      |    |     |     |
|      |          |                          | 2013 Aug 8 doi:             |      |    |     |     |
|      |          |                          | 2013 Aug 0. $001$ .         |      |    |     |     |
|      |          |                          | 10.1002/hep.200             |      |    |     |     |
|      |          |                          | //. [Epub ahead             |      |    |     |     |
|      |          |                          | of print]                   |      |    |     |     |
| 2013 |          | Cheung KF,               | CITED2 is a                 | 2013 | No | Yes | yes |
|      |          | Zhao J, Hao              | novel direct                |      |    |     |     |
|      |          | Y, Li X,                 | effector of                 |      |    |     |     |
|      |          | Lowe AW.                 | peroxisome                  |      |    |     |     |
|      |          | Cheng AS                 | proliferator-activ          |      |    |     |     |
|      |          | Sung II Vu               | ated recentor v             |      |    |     |     |
|      |          | I*                       | in suppressing              |      |    |     |     |
|      |          | <u>J .</u> .             | In suppressing              |      |    |     |     |
|      |          |                          | nepatocenular               |      |    |     |     |
|      |          |                          | carcinoma cell              |      |    |     |     |
|      |          |                          | growth.                     |      |    |     |     |
|      |          |                          | Cancer 2013,                |      |    |     |     |
|      |          |                          | 119:1217-26                 |      |    |     |     |
| 2013 |          | Wang J,                  | Inhibitory role             | 2013 | No | Yes | yes |
|      |          | Zhao J, Chu              | of Smad7 in                 |      |    |     | -   |
|      |          | ES. Mok                  | hepatocarcinoge             |      |    |     |     |
|      |          | MT. Go MY                | nesis in mice               |      |    |     |     |
|      |          | Man K                    | and in vitro                |      |    |     |     |
|      |          | Houshal D                |                             |      |    |     |     |
|      |          | Len IIV                  | J FUINOL 2013;              |      |    |     |     |
|      |          | Lan $HY$ ,               | 230: 441–452                |      |    |     |     |
|      |          | Chang Z,                 |                             |      |    |     |     |
|      |          | Sung JJ, <u>Yu</u>       |                             |      |    |     |     |
|      |          | <u>J*</u> .              |                             |      |    |     |     |

**9.** Recognized international conference(s) in which paper(s) related to this research project was/were delivered (*Please attach a copy of each conference abstract*)

| Month<br>/Year<br>/place         | Title   | Conference<br>Name                   | Submitted<br>to RGC<br>(indicate<br>the year<br>ending of<br>the<br>relevant<br>progress<br>report) | Attached<br>to this<br>report<br>(Yes or<br>No) | Acknowled<br>ged the<br>support of<br>RGC (Yes<br>or No) | Accessible<br>from the<br>institutiona<br>l<br>repository<br>(Yes or<br>No) |
|----------------------------------|---|--------------------------------------|---|---|--|---|
| August,<br>2016,<br>Hong<br>Kong | Up-regulation of GSTA2 at<br>early-phase after liver<br>transplantation increases the risk<br>of late-phase hepatocellular<br>carcinoma recurrence.         | Internation<br>al Congress<br>of TTS | No  | Yes   | Yes  | Yes   |
| August,<br>2016,<br>Hong<br>Kong | The clinical significance and<br>potential therapeutic role of GPx3<br>in tumor recurrence after liver<br>transplantation.                                  | Internation<br>al Congress<br>of TTS | No  | Yes   | Yes  | Yes   |
| August,<br>2016,<br>Hong<br>Kong | AMP-activated protein kinase<br>attenuated marginal liver graft<br>injury via promoting mitochondrial<br>biogenesis and respiratory<br>function.            | Internation<br>al Congress<br>of TTS | No  | Yes   | Yes  | Yes   |
| August,<br>2016,<br>Hong<br>Kong | Stem cell like memory B cells<br>attenuate hepatitis B virus relapse<br>in hepatocellular carcinoma<br>patients post liver transplantation                  | Internation<br>al Congress<br>of TTS | No  | Yes   | Yes  | Yes   |
| August,<br>2016,<br>Hong<br>Kong | Clinical significance of transforming<br>growth factor beta receptor III<br>(TGFβR3) with its suppressive role<br>on tumor associated macrophages<br>in HCC | Internation<br>al Congress<br>of TTS | No  | Yes   | Yes  | Yes   |

| <b>CRF 8G</b> (1                 | Revised Sep 15)   |   |    |     |     |     |
|----------------------------------|---|---|----|-----|-----|-----|
| August,<br>2016,<br>Hong<br>Kong | Inflammasome exacerbated fatty<br>graft injury with accumulation of<br>myeloid-derived suppressor cells<br>after living donor liver<br>transplantation        | Internation<br>al Congress<br>of TTS              | No | Yes | Yes | Yes |
| August,<br>2016,<br>Hong<br>Kong | Repressor and activator protein<br>accelerates hepatic ischemia<br>reperfusion injury by promoting<br>neutrophil inflammatory response                        | Internation<br>al Congress<br>of TTS              | No | Yes | Yes | Yes |
| August,<br>2016,<br>Hong<br>Kong | Liver regeneration was attenuated<br>by deletion of CXCL10 or its<br>receptor CXCR3 via YAP1 signaling  | Internation<br>al Congress<br>of TTS              | No | Yes | Yes | Yes |
| August,<br>2016,<br>Hong<br>Kong | Atg5/Atg7-independent<br>macroautophagy mediates hepatic<br>sinusoidal endothelial cells'<br>response to ischemia-reperfusion<br>injury                       | Internation<br>al Congress<br>of TTS              | No | Yes | Yes | Yes |
| May,<br>2016,<br>Seoul           | Early-phase up-regulation of<br>glutathione S-transferase A2<br>promotes late-phase<br>hepatocellular carcinoma<br>recurrence after liver<br>transplantation. | ILTS 22nd<br>Annual<br>Internation<br>al Congress | No | Yes | Yes | Yes |
| May,<br>2016,<br>Seoul           | A novel oxygen carrier sensitized<br>Cisplatin based chemotherapy in<br>hepatocellular carcinoma.   | ILTS 22nd<br>Annual<br>Internation<br>al Congress | No | Yes | Yes | Yes |
| May,<br>2016,<br>Seoul           | AMP-activated protein kinase<br>attenuated marginal liver graft<br>injury via promoting mitochondrial<br>biogenesis and respiratory<br>function.              | ILTS 22nd<br>Annual<br>Internation<br>al Congress | No | Yes | Yes | Yes |

| <b>CRF 8G</b> (1              | Revised Sep 15)  |   |    |     |     |     |
|-------------------------------|--|---|----|-----|-----|-----|
| May,<br>2016,<br>Seoul        | M2 macrophages activated by Toll<br>like receptor 4 signaling accelerate<br>tumor recurrence after liver<br>transplantation.   | ILTS 22nd<br>Annual<br>Internation<br>al Congress   | No | Yes | Yes | Yes |
| May,<br>2015,<br>Hong<br>Kong | Regulatory B cells accelerate<br>hepatocellular carcinoma<br>pregression via CD40/CD154<br>signaling pathway.  | Internation<br>al<br>Symposium<br>on<br>Transplanta<br>tion &<br>Cancer<br>Immunolog<br>y | No | Yes | Yes | Yes |
| May,<br>2015,<br>Hong<br>Kong | The knockout of Rap1 accelerates<br>liver regeneration after<br>transplantation.   | Internation<br>al<br>Symposium<br>on<br>Transplanta<br>tion &<br>Cancer<br>Immunolog<br>y | No | Yes | Yes | Yes |
| May,<br>2015,<br>Hong<br>Kong | NLRP3 inflammasome induced<br>graft injury regulated by<br>telomere-independent repressor<br>activator protein 1 (RAP1) /<br>keratinocyte chemoattractant (KC)<br>axis after LDLT. | Internation<br>al<br>Symposium<br>on<br>Transplanta<br>tion &<br>Cancer<br>Immunolog<br>y | No | Yes | Yes | Yes |
| May,<br>2015,<br>Hong<br>Kong | Glutathione Peroxidase 3 (GPx3)<br>suppressed HCC invasiveness<br>through JNK-cJun-MMP2 signaling<br>pathway   | Internation<br>al<br>Symposium<br>on<br>Transplanta<br>tion &<br>Cancer<br>Immunolog<br>y | No | Yes | Yes | Yes |
| May,<br>2015,<br>Hong<br>Kong | Increased tumor recurrence by M2<br>macrophages after liver<br>transplantation   | Internation<br>al<br>Symposium<br>on<br>Transplanta<br>tion &<br>Cancer<br>Immunolog<br>y | No | Yes | Yes | Yes |

| <b><u>CRF 8G</u></b> (1 | Revised Sep 15)  |                   |     |     |     |     |
|-------------------------|--|-------------------|-----|-----|-----|-----|
| May,<br>2015,           | Post-transplant Bregs promote the tumor recurrence via | Internation<br>al | No  | Yes | Yes | Yes |
| Hong                    | CXCL10/CXCR3 signaling                                 | Symposium         |     |     |     |     |
| Kong                    |  | on                |     |     |     |     |
|                         |  | Transplanta       |     |     |     |     |
|                         |  | tion &            |     |     |     |     |
|                         |  | Cancer            |     |     |     |     |
|                         |  | Immunolog         |     |     |     |     |
|                         |  | У                 |     |     |     |     |
| May,                    | The roles of IP10 in liver                             | Internation       | No  | Yes | Yes | Yes |
| 2015,                   | regeneration and tissue repair are                     | al                |     |     |     |     |
| Hong                    | cell type dependent                                    | Symposium         |     |     |     |     |
| копд                    |  | ON<br>Transplanta |     |     |     |     |
|                         |  | tion &            |     |     |     |     |
|                         |  | Cancer            |     |     |     |     |
|                         |  | Immunolog         |     |     |     |     |
|                         |  | v                 |     |     |     |     |
| Julv.                   | Glutathione Peroxidase 3 (GPx3)                        | ,<br>ILTS 21st    | No  | Yes | Yes | Yes |
| 2015,                   | suppressed HCC invasiveness                            | Annual            |     |     |     |     |
| USA                     | through JNK-cJun-MMP2 signaling                        | Internation       |     |     |     |     |
|                         | pathway - Application of in vivo                       | al Congress       |     |     |     |     |
|                         | real-time molecular imaging.                           |                   |     |     |     |     |
|                         |  |                   |     |     |     |     |
|                         |  |                   |     |     |     |     |
|                         |  |                   |     |     |     |     |
| Nov.                    | Clinical significance and                              | 21st Hong         | No  | Yes | Yes | Yes |
| 2014,                   | therapeutic value of Glutathione                       | Kong              |     |     |     |     |
| Hong                    | Peroxidase 3 (GPx3) in                                 | Internation       |     |     |     |     |
| Kong                    | Hepatocellular carcinoma                               | al Cancer         |     |     |     |     |
|                         |  | Congress          |     |     |     |     |
| Nov,                    | Regulatory B cells accelerate                          | 22nd Hong         | No  | Yes | Yes | Yes |
| 2014,                   | hepatocellular carcinoma                               | Kong              |     |     |     |     |
| Hong                    | pregression via CD40/CD154                             | Internation       |     |     |     |     |
| Kong                    | signaling pathway                                      | al Cancer         |     |     |     |     |
|                         |  | Congress          |     |     |     |     |
|                         |  |                   |     |     |     |     |
| May                     | Mutations in Cel and Hras1 Are                         | Digestive         | No  | Vec | Ves | Ves |
| 2014.                   | Associated With  | Disease           |     | 105 | 103 | 105 |
| USA                     | Obesity-Associated Hepatocellular                      | Week 2014         |     |     |     |     |
|                         | Carcinoma.   |                   |     |     |     |     |
|                         |  |                   |     |     |     |     |
| Maria                   |  | Digestive         | Nia | Vac | Var | Var |
| 1VIay,                  | Hepatic CXCR3 Promotes                                 | Digestive         | NO  | res | res | Yes |
| 2014,                   | Through Inflammation Linid                             | Week 2014         |     |     |     |     |
| USA                     | Accumulation and Autophagy                             | VVEEN 2014        |     |     |     |     |
|                         | Deficiency   |                   |     |     |     |     |
|                         | Denotency.   |                   |     |     |     |     |
|                         |  |                   |     |     |     |     |

| <u>CRF 8G</u> (1                       | Revised Sep 15)   |   |    |     |     |     |
|--|---|---|----|-----|-----|-----|
| May,<br>2014,<br>USA                   | Decreased Lysosomal Function<br>Impairs Autophagosome<br>-Lysosome System in a Dietary<br>Mice Model of Non-Alcoholic Fatty<br>Liver Disease.               | Digestive<br>Disease<br>Week 2014               | No | Yes | Yes | Yes |
| May,<br>2014,<br>USA                   | Inducible Macrophage Ablation<br>Protects Mice From Non-Alcoholic<br>Steatohepatitis.   | Digestive<br>Disease<br>Week 2014               | No | Yes | Yes | Yes |
| October,<br>2015,<br>Spain             | Role of Squalene Epoxidase (SQLE)<br>in promoting fatty liver<br>disease-associated liver cancer.   | United<br>European<br>Gastroente<br>rol J. 2015 | No | Yes | Yes | Yes |
| October,<br>2015,<br>Spain             | Genomic mutations and pathways<br>identified by whole-exome<br>sequencing in NAFLD-associated<br>hepatocellular carcinoma.                                  | United<br>European<br>Gastroente<br>rol J. 2015 | No | Yes | Yes | Yes |
| October,<br>2015,<br>Spain             | O-GlcNAc transferase promotes<br>fatty liver-associated liver cancer<br>through activating JNK and NF-κB<br>pathways.                                       | United<br>European<br>Gastroente<br>rol J. 2015 | No | Yes | Yes | Yes |
| October,<br>2015,<br>Spain             | CXCL10 Mediates the Impairment<br>of Autophagosome-lysosome<br>System through Lysosome<br>Dysfunction in Steatohepatitis.                                   | United<br>European<br>Gastroente<br>rol J. 2015 | No | Yes | Yes | Yes |
| May,<br>2016, San<br>Diego,<br>CA, USA | CXC Chemokine Receptor 3 Causes<br>Mitochondrial Dysfunction in the<br>Development of Non-Alcoholic<br>Steatohepatitis.                                     | United<br>European<br>Gastroente<br>rol J. 2015 | No | Yes | Yes | Yes |
| May,<br>2016,<br>USA                   | Bone Marrow-Derived Macrophage<br>Contributes to Hepatic Nutritional<br>Fibrosis Through Activating Hepatic<br>Stellate Cells in Mice and <i>in vitro</i> . | United<br>European<br>Gastroente<br>rol J. 2015 | No | Yes | Yes | Yes |

| <b>CRF 8G</b> (1            | Revised Sep 15)   |  |      |    |     |     |
|-----------------------------|---|--|------|----|-----|-----|
| July/2014<br>/USA           | Hepatic Senescence Associated<br>Down-regulation of Glutathione<br>Peroxidase 3 (GPx3) Promoted<br>Tumor Recurrence after Living<br>Donor Liver Transplantation                   | World<br>Transplant<br>Congress  | 2015 | No | Yes | Yes |
| July/2014<br>/USA           | The knockout of Rap1 accelerates<br>liver regeneration after<br>transplantation   | World<br>Transplant<br>Congress  | 2015 | No | Yes | Yes |
| June/201<br>4/UK            | Knockout of<br>Telomere-independent Rap1<br>Attenuates Hepatic Ischemia<br>Reperfusion Injury by Suppressing<br>Neutrophil Activation.  | The 2014<br>Joint<br>Internation<br>al Congress<br>of ILTS,<br>ELITA &<br>LICAGE | 2015 | No | Yes | Yes |
| June/201<br>4/UK            | NLRP3 Inflammasome Regulated by<br>Telomere-independent Repressor<br>Activator Protein1(RAP1) Induced<br>Graft Injury after LDLT  | The 2014<br>Joint<br>Internation<br>al Congress<br>of ILTS,<br>ELITA &<br>LICAGE | 2015 | No | Yes | Yes |
| June/201<br>4/UK            | The Role of RAP1 in Graft Injury<br>Induced Cisplatin Resistance after<br>Liver Transplantation.  | The 2014<br>Joint<br>Internation<br>al Congress<br>of ILTS,<br>ELITA &<br>LICAGE | 2015 | No | Yes | Yes |
| June/201<br>4/UK            | The Roles of IP10 in Liver<br>Regeneration and Tissue Repair Are<br>Cell Type Dependent   | The 2014<br>Joint<br>Internation<br>al Congress<br>of ILTS,<br>ELITA &<br>LICAGE | 2015 | No | Yes | Yes |
| June/201<br>3/Singapo<br>re | Transplantation of human<br>iPSC-derived MSC promotes liver<br>regeneration and reduces<br>inflammation attributed to<br>paracrine actions-mediated<br>macrophage depolarization. | The APASL<br>Liver Week<br>2013  | 2015 | No | Yes | Yes |

| <b>CRF 8G</b> (1 | Revised Sep 15)                      |                        |      |     |     |     |
|------------------|--------------------------------------|------------------------|------|-----|-----|-----|
| Nov/2013         | The knockout of                      | 3 <sup>rd</sup> ESOT   | 2013 | No  | Yes | Yes |
| /France          | telomere-independent Rap1            | Basic                  |      |     |     |     |
|                  | attenuates liver graft injury by     | Science                |      |     |     |     |
|                  | suppressing macrophage activation    | Meeting &              |      |     |     |     |
|                  |                                      | 13 <sup>th</sup> TTS   |      |     |     |     |
|                  |                                      | Basic                  |      |     |     |     |
|                  |                                      | Science                |      |     |     |     |
|                  |                                      | Symposium              |      |     |     |     |
| June /           | The role of Interferon-gamma         | ILTS 19 <sup>th</sup>  | 2013 | No  | Yes | Yes |
| 2013/            | Inducible Protein 10 (IP10) in acute | Annual                 |      |     |     |     |
| Sydney,          | phase graft injury induced cisplatin | Internation            |      |     |     |     |
| Australia        | resistance after liver               | al                     |      |     |     |     |
|                  | transplantation                      | Congress.              |      |     |     |     |
|                  |                                      |                        |      |     |     |     |
| lune /           | Telomere-Independent Ran1            | II TS 19 <sup>th</sup> | 2013 | No  | γρς | γρς |
| 2013/            | Accelerates Small-For-Size Liver     | Annual                 | 2015 | NO  | 105 | 105 |
| Sydney           | Graft Injury by Enhancing Liver      | Internation            |      |     |     |     |
| Australia        | Inflammatory Responses.              | al                     |      |     |     |     |
| , aser and       |                                      | Congress.              |      |     |     |     |
| June /           | Glutathione peroxidase 3 (GPx3)      | ILTS 19 <sup>th</sup>  | 2013 | No  | Yes | Yes |
| 2013/            | delivered by mesenchymal stem        | Annual                 |      |     |     |     |
| Svdnev.          | cells (MSC) ameliorates hepatic      | Internation            |      |     |     |     |
| Australia        | ischemia/reperfusion injuries.       | al                     |      |     |     |     |
|                  |                                      | Congress.              |      |     |     |     |
|                  | M2 magraphagas promoto tumor         |                        | 2012 | No  | Vac | Vec |
| June /           | growth and invasion in               | 2012 confe             | 2013 | INO | res | res |
| 2013/118         | henatocellular carcinoma             | rence                  |      |     |     |     |
| nee              |                                      | Tenee                  |      |     |     |     |
| May /            | Acute phase circulating micoRNAs     | II TS 18 <sup>th</sup> | 2013 | No  | Ves | Ves |
| 2012/1154        | nredict tumor recurrence and         |                        | 2015 | NO  | 163 | 163 |
| 2012/03A         | survivals of henatocellular          | Internation            |      |     |     |     |
|                  | carcinoma natients after liver       | al                     |      |     |     |     |
|                  | transplantation                      | Congress               |      |     |     |     |
|                  |                                      | congress.              |      |     |     |     |
|                  |                                      | u <del> t</del> h      |      |     |     |     |
| May /            | Novel mechanism for tissue repair    | ILTS 18"               | 2013 | No  | Yes | Yes |
| 2012/USA         | of human induced pluripotent stem    | Annual                 |      |     |     |     |
|                  | cells derived mesenchymal stem       | Internation            |      |     |     |     |
|                  | cells during liver regeneration      | al                     |      |     |     |     |
|                  |                                      | Congress.              |      |     |     |     |
|                  |                                      |                        |      |     |     |     |
| May /            | Acute Phase Liver Graft Injury       | ILTS 18 <sup>th</sup>  | 2013 | No  | Yes | Yes |
| 2012/USA         | Mobilizes Regulating B cells after   | Annual                 |      |     |     |     |
|                  | LDLT for HCC Patients Through        | Internation            |      |     |     |     |
|                  | TLR4/CXCL10/CXCR3 Signaling          | al                     |      |     |     |     |
|                  |                                      | Congress.              |      |     |     |     |
|                  |                                      |                        |      |     |     |     |
|                  |                                      |                        |      |     |     |     |

| <b>CRF 8G</b> (I                              | Revised Sep 15)  |   |      |    |     |     |
|---|--|---|------|----|-----|-----|
| May /<br>2012/USA                             | Alternative activation of<br>macrophages by liver graft injury<br>promotes tumor recurrence after<br>LDLT for HCC patients   | ILTS 18 <sup>th</sup><br>Annual<br>Internation<br>al<br>Congress.                       | 2013 | No | Yes | Yes |
| July/2012<br>/Germany                         | Actue phase graft injury promotes<br>tumor invasiveness through<br>down-regulation of Glutathione<br>Peroxidase 3 (GPx3) after liver<br>transplantation  | 24 <sup>th</sup><br>Internation<br>al Congress<br>of The<br>Transplanta<br>tion Society | 2013 | No | Yes | Yes |
| July/2012<br>/Germany                         | Acute Phase Graft Injury Mobilizes<br>Regulating B cells after Living<br>Donor Liver Transplantation for the<br>Patients with Hepatocellular<br>Carcinoma through<br>TLR4/CXCL10/CXCR3 Signaling | 24 <sup>th</sup><br>Internation<br>al Congress<br>of The<br>Transplanta<br>tion Society | 2013 | No | Yes | Yes |
| May<br>19-22,<br>2013,<br>Orlando,<br>FL, USA | MicroRNA-29b Prevents Liver<br>Fibrosis by Attenuating Hepatic<br>Stellate Cell Activation and<br>Inducing Apoptosis In Vitro and in<br>Mice.  | The<br>Digestive<br>Disease<br>Week   | 2013 | No | Yes | Yes |
| May<br>19-22,<br>2013,<br>Orlando,<br>FL, USA | Role of interferonγ-inducible<br>protein 10 in the pathogenesis of<br>non-alcoholic steatohepatitis.   | The<br>Digestive<br>Disease<br>Week   | 2013 | No | Yes | Yes |
| May<br>19-22,<br>2013,<br>Orlando,<br>FL, USA | CXCL10 induces hepatocyte<br>apoptosis and autophagy in<br>experimental non-alcoholic<br>steatohepatitis   | The<br>Digestive<br>Disease<br>Week   | 2013 | No | Yes | Yes |
| May<br>19-22,<br>2013,<br>Orlando,<br>FL, USA | Inhibitory Role of Peroxisome<br>Proliferator-Activated Receptor<br>Alpha in Hepatocarcinogenesis in<br>Mice.  | The<br>Digestive<br>Disease<br>Week   | 2013 | No | Yes | Yes |
| May<br>19-22,<br>2013,<br>Orlando,<br>FL, USA | BCL6B Inhibits Hepatocellular<br>Carcinoma Metastases In Vitro and<br>in Mice.   | The<br>Digestive<br>Disease<br>Week   | 2013 | No | Yes | Yes |

| <b>CRF 8G</b> (1                              | Revised Sep 15)  |   |      |    |     |     |
|---|--|---|------|----|-----|-----|
| May<br>19-22,<br>2013,<br>Orlando,<br>FL, USA | Epigenetic Inactivation of Claudin 3<br>in Hepatocellular Carcinoma and Its<br>Functional Consequences.  | The<br>Digestive<br>Disease<br>Week   | 2013 | No | Yes | Yes |
| June/201<br>3/Singapo<br>re                   | Transplantation of human<br>iPSC-derived MSC promotes liver<br>regeneration and reduces<br>inflammation attributed to<br>paracrine actions-mediated<br>macrophage depolarization | Asian<br>Pacific<br>Association<br>for the<br>Study of<br>the Liver<br>2013 | 2013 | No | Yes | Yes |

# **10.** *Student(s) trained* (please attach a copy of the title page of the thesis)

| Name                | Degree<br>registered<br>for | Date of registration | Date of thesis<br>submission/<br>graduation |
|---------------------|-----------------------------|----------------------|---|
| Chang Chun LING     | PhD                         | Jan-08               | Apr-12                                      |
| Wei GENG            | PhD                         | Sep-09               | Dec-12                                      |
| Oscar Wai Ho YEUNG  | PhD                         | Jun-09               | May-13                                      |
| Ming LIU            | PhD                         | Sep-09               | Aug-13                                      |
| Chang Xiang LI      | PhD                         | May-12               | Jul-16                                      |
| Cindy Ka Yee CHEUNG | PhD                         | 2009                 | 2015  |
| Xiang Qi            | PhD                         | 1-Jan-10             | 1-Dec-13                                    |
| Wilson Wu           | PhD                         | 2008                 | 2012  |
| Junhong Zhao        | PhD                         | 2009                 | 2012  |
| Yujuan Dong         | PhD                         | 2009                 | 2012  |
| Jun He              | PhD                         | 2009                 | 2013  |
| Nana Zhu            | PhD                         | 2010                 | 2013  |
| Jia Wang            | PhD                         | 2010                 | 2013  |
| Jiayun Shen         | PhD                         | 2010                 | 2013  |
| Xiang Zhang         | PhD                         | 2011                 | 2014  |
| Lixia Xu            | PhD                         | 2011                 | 2014  |
| Xiaojuan Wang       | PhD                         | 2012                 | 2015  |
| Kunning Wang        | PhD                         | 2012                 | 2015  |
| Xue Xiao            | PhD                         | 2012                 | 2015  |
| Lingxi Jiang        | PhD                         | Sep-12               | Jun-16                                      |
| Siu Ming Chiu       | MPhil                       | Sep-11               | Oct-13                                      |
| Senwei Tang         | Mphil                       | 2013                 | 2015  |

**11. Other impact** (*e.g. award of patents or prizes, collaboration with other research institutions, technology transfer, etc.*)

| Recipient          | Award                                      | Year | Awarder   |
|--------------------|--|------|---|
| Lo Chung Mau       | Mentor and Mentee<br>Traval Award (Mentor) | 2016 | The Transplantation<br>Society (TTS)  |
| Man Kwan           | Mentor and Mentee<br>Traval Award (Mentor) | 2016 | The Transplantation<br>Society (TTS)  |
| Qi Xiang           | Mentor and Mentee<br>Traval Award (Mentee) | 2016 | The Transplantation<br>Society (TTS)  |
| Liu Jiang          | Mentor and Mentee<br>Traval Award (Mentee) | 2016 | The Transplantation<br>Society (TTS)  |
| Ng Kevin Tak Pan   | Young Investigator<br>Award                | 2016 | The Transplantation<br>Society (TTS)  |
| Yeung Oscar Wai Ho | Young Investigator<br>Award                | 2016 | The Transplantation<br>Society (TTS)  |
| Liu Jiang          | Young Investigator<br>Award                | 2016 | International Liver<br>Transplantation<br>Society (ILTS)                              |
| Li Chang Xiang     | Rising Star Award                          | 2016 | International Liver<br>Transplantation<br>Society (ILTS)                              |
| Yu Jun             | Croucher Senior<br>Research Fellowship     | 2016 | Croucher foundation,<br>Hong Kong   |
| Man Kwan           | Mentor and Mentee<br>Award (Mentor)        | 2015 | The Transplantation<br>Society (TTS)  |
| Li Chang Xiang     | Mentor and Mentee<br>Award (Mentee)        | 2015 | The Transplantation<br>Society (TTS)  |
| Qi Xiang           | Young Investigator<br>Award                | 2015 | International Liver<br>Transplantation<br>Society (ILTS)                              |
| Shao Yan           | Outstanding<br>Presentation Award          | 2015 | International<br>Symposium on<br>Transplantation &<br>Cancer Immunology,<br>Hong Kong |
| Qi Xiang           | Outstanding<br>Presentation Award          | 2015 | International<br>Symposium on<br>Transplantation &<br>Cancer Immunology,<br>Hong Kong |
| Liu Hui            | Outstanding<br>Presentation Award          | 2015 | International<br>Symposium on<br>Transplantation &<br>Cancer Immunology,<br>Hong Kong |

| CRI OG (REVISED SE  | P 13)   |      |   |
|---|---|------|---|
| Li Chang Xiang  | Outstanding<br>Presentation Award                                     | 2015 | International<br>Symposium on<br>Transplantation &<br>Cancer Immunology,<br>Hong Kong |
| Li Chang Xiang  | YS and Christabel<br>Lung Postgraduate<br>Scholarship                 | 2015 | Faculty of Medicine,<br>The University of<br>Hong Kong                                |
| Yu Jun  | Outstanding Fellow of<br>the Faculty of Medicine                      | 2015 | The Chinese<br>University of Hong<br>Kong   |
| Li Chang Xiang  | Wong Ching Yee<br>Medical Postgraduate<br>Scholarship                 | 2014 | Faculty of Medicine,<br>The University of<br>Hong Kong                                |
| Li Chang Xiang  | Mentor and Mentee<br>Award (Mentee)                                   | 2014 | TTS and ILTS  |
| Man Kwan  | Mentor and Mentee<br>Award (Mentor)                                   | 2014 | TTS and ILTS  |
| Lo Chung Mau, Man<br>Kwan, Ng Kevin Tak<br>Pan, Li Chang Xiang,<br>Geng Wei, Liu Xiao<br>Bing | The Chinese Medical<br>Technology Award,<br>First Class               | 2014 | The Chinese Medical<br>Association, China   |
| Lo Chung Mau, Man<br>Kwan, Ng Kevin Tak<br>Pan  | The Natural Science<br>Award, First Class                             | 2014 | Ministry of Education,<br>China   |
| Qi Xiang  | Poster Award  | 2014 | Hong Kong<br>International Cancer<br>Congress   |
| Yu Jun  | The Natural Science<br>Award, First Class                             | 2014 | Ministry of Education,<br>China   |
| Yeung Oscar Wai Ho  | Best Research Output<br>Award   | 2014 | Department of<br>Surgery, The<br>University of Hong<br>Kong                           |
| Chang Chung Ling  | Best Research Output<br>Award   | 2013 | Department of<br>Surgery, The<br>University of Hong<br>Kong                           |
| Yu Jun  | State Scientific and<br>Technological Progress<br>Award, Second Class | 2012 | Ministry of Science<br>and Technology of the<br>People's Republic of<br>China         |
| Yu Jun  | Science and<br>Technology Progress<br>Award, First Class              | 2012 | Ministry of Education,<br>China   |
| Man Kwan  | TTS Basic Science<br>Mentor and Mentee<br>Travel Award (Mentor)       | 2013 | The Transplantation<br>Society (TTS)  |

# CRF 8G (Revised Sep 15)

| Man Kwan           | TTS Basic Science<br>Mentor and Mentee<br>Travel Award (Mentor) | 2012      | The Transplantation<br>Society (TTS)                     |
|--------------------|---|-----------|--|
| Li Chang Xian      | TTS Basic Science<br>Mentor and Mentee<br>Travel Award (Mentee) | 2013      | The Transplantation<br>Society (TTS)                     |
| Ma Yuen Yuen       | The Young Investigator<br>Award                                 | 2012      | International Liver<br>Transplantation<br>Society (ILTS) |
| Ng Kevin Tak Pan   | The Young Investigator<br>Award                                 | 2012      | International Liver<br>Transplantation<br>Society (ILTS) |
| Yeung Oscar Wai Ho | Travel Award  | 2013      | 18th NAT<br>2013 conference                              |
| Qi Xiang           | TTS Basic Science<br>Mentor and Mentee<br>Traval Award (Mentee) | 2012      | The Transplantation<br>Society (TTS)                     |
| Guan Xin-Yuan      | Outstanding Researcher<br>Award                                 | 2011-2012 | The University of<br>Hong Kong                           |
| Li Yan             | Li Ka Shing Prizes  | 2011-2012 | The University of<br>Hong Kong                           |
| Liu Ming           | Mary Sun Medical<br>Scholarship<br>(Postgraduate)               | 2011-2012 | The University of<br>Hong Kong                           |
| Liu Ming           | YS and Christabel<br>Lung Postgraduate<br>Scholarship           | 211-2012  | The University of<br>Hong Kong                           |
| Liu Ming           | Joseph Shuk-Cho Lung<br>Memorial Scholarship                    | 2011-2012 | The University of<br>Hong Kong                           |
| Liu Ming           | Yu To Sang and Yu<br>Shing Keung Memorial<br>Fund Scholarship   | 2011-2012 | The University of<br>Hong Kong                           |

CRF 8G (Revised Sep 15)

**Project Coordinator** 

Contact Information:

chungmlo@hku.hk